Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis

Ann Hepatol. 2017 March-April;16(2):188-197. doi: 10.5604/16652681.1231562.

Authors

Mohammad S Rezaee-Zavareh¹, Khashayar Hesamizadeh², Bita Behnava², Seyed M Alavian², Mohammad Gholami-Fesharaki³, Heidar Sharafi²

Affiliations

¹ Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
² Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran.
³ Department of Biostatistics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, IR Iran.

PMID: 28233739
DOI: 10.5604/16652681.1231562

No abstract available

Keywords: Hepatitis C; Ledipasvir; meta-analysis; sofosbuvir; therapy.

Publication types

Meta-Analysis
Review
Systematic Review

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Antiviral Agents / adverse effects
Antiviral Agents / therapeutic use*
Benzimidazoles / adverse effects
Benzimidazoles / therapeutic use*
Chi-Square Distribution
Drug Therapy, Combination
Female
Fluorenes / adverse effects
Fluorenes / therapeutic use*
Genotype
Hepacivirus / drug effects*
Hepacivirus / genetics
Hepatitis C / diagnosis
Hepatitis C / drug therapy*
Hepatitis C / virology
Humans
Male
Middle Aged
Odds Ratio
Ribavirin / therapeutic use
Sofosbuvir / adverse effects
Sofosbuvir / therapeutic use*
Sustained Virologic Response
Time Factors
Treatment Outcome
Young Adult

Substances

Antiviral Agents
Benzimidazoles
Fluorenes
ledipasvir
Ribavirin
Sofosbuvir